

**Foundation for Osteopathic Emergency Medicine
BOARD OF TRUSTEES
July 29, 2014
Conference Call
Minutes**

Members Present:

Sherry Turner, D.O., FACOEP, President
Juan Acosta, D.O., MS, Ph.D., FACOEP-D, Immediate Past President
Michael Allswede, D.O.
Steve Hollosi, D.O.
Joseph Kissinger
Victor J. Scali, D.O., FACOEP-D
Robert Suter, D.O., FACOEP-D
Shelly Zimmerman-Damon, D.O., FACOEP
Janice Wachtler, BAE, CBA, Executive Director
Stephanie Whitmer, Assistant Executive Director

Not Present:

Peter J. Kaplan, President-Elect
William F. Lynch, Secretary
Rudolph Beschere, Jr., D.O., FACOEP
Aimee Blagovich, D.O.

The meeting was called to order at 9:04 a.m. by Sherry Turner, D.O., FACOEP – President. A motion was made to accept the minutes from May 27, 2014. The motion was seconded and the Minutes were approved as written.

Officer's Reports

Dr. Turner reported no news; Mr. Kaplan and Mr. Lynch were not on the call.

Treasurer's Report

As there was no Treasurer at this time, Ms. Whitmer reported that FOEM has \$330,000.00 in checking, savings, and investments.

Competition Update

Ms. Whitmer reported that there are only 22 total applications at this time. While the new online application process is going well, the residents tend to wait until the last minute to submit. Dr. Hollosi, Dr. Allswede, and Dr. Acosta volunteered as emcees for the competitions in Las Vegas. Drs. Scali, Turner, and Zimmerman-Damon volunteered to screen the applications prior to Las Vegas.

Legacy Gala

Ms. Whitmer reported that the Gala is short on sponsorship revenue, and recommended the Board reach out to their various contacts with the new marketing materials and prospectus. She reported that the Event Planning Committee met last month and designated roles, responsibilities, and deadlines to plan the event.

FOEM Research Network

Dr. Scali submitted a written report (attached) and reported that he met with the Boeringer Ingelheim(BI) Clinical Research Coordinator and that they are using 14 of the FRN sites for their anticoagulant study. He asked Ms. Whitmer to resubmit the original FRN documents to him to be pared down and simplified as marketing pieces for pharma and potential research sites.

Faculty Development Track

Ms. Wachtler reported that she retyped the FDC curriculum and added educational and course objectives in order for it to be ACCME accredited in the fall. She reported that while the October 2014 speakers and topics are set, the next three sessions are not finalized. The Board decided on a process in which they make speaker and topic recommendations to the ACOEP, who then contracts speakers. FOEM will then reimburse ACOEP for expenses up to \$17,000 over 3 – 5 years.

Treasurer Election

Dr. Hollosi volunteered to be Treasurer. The Board voted and approved his nomination.

As there was no further business, the meeting was adjourned at 9:46 a.m.

Respectfully submitted,

Stephanie Whitmer
Assistant Executive Director

July 28, 2014

To: FOEM Board of Directors
From: Victor J. Scali DO, FACOEP-D
FRN Steering Committee Chair
Sub: Progress Report FRN

Dear colleagues:

I am happy to report that FRN is making very good progress towards one of our two primary goals: Engaging Pharma to use the FRN for some of their current national study protocols. In May ,I met with Boeringer Ingelheim(BI) Clinical Research Coordinator, after our Hospital , Kennedy Health System, was chosen as a site for their protocol which will be testing a new experimental reversal agent for Pradaxa, an anticoagulant with the potential for life threatening bleeding and currently no way to reverse the agent. I introduced the FOEM Research Network and offered our databases for member residencies to her at no charge and as a service to the industry. BI chose 14 of our member sites to contact as possible sites for the study, and 8 sites are currently pursuing the acceptance process. Not bad for a study with a 150 sites to recruit.

In June I met with Astra Zeneca Research Coordinator, Alex Schlesinger, and also introduced the FRN concept and value added. He has taken my information back to research department and is very enthusiastic about it. I am awaiting a reply to possibly engage some of our sites in 2 current studies: #1 SOCRATES and UPSTREAM.

I also have just begun contact with Genentech Research Department. They have some new lytic trials coming.

Peter and I spoke about developing some dynamic marketing pieces that could be left with pharmaceutical companies rather than just using the website descriptive piece. Peter and I have developed a little elevator speech for quick conversation.

Here is where we need to go from here:

1. Continue developing our FRN dedicated website
2. Expand the information databases of existing members based on clinical director interview. Essentially asking them what information is most valuable about the site
3. Print FRN business cards
4. Have quarterly conference call with Steering Committee members
5. Develop a cadre of individuals doing what I am doing contacting Pharma and following up on inquiries
6. Deliver Marketing pieces under internal development by Peter and print
7. Consider NACRI data collection system in future for PHARMA ,as they cannot use REDCAP for commercial purposes
8. Engage REDCAP for resident multicenter projects not funded by pharma or device companies
9. Engage steering committee members with their great expertise

Board member input and support is most appreciated. I am available now at your command